The Impact of Various Cellular Product Characteristics on the Efficacy of Anti-CD19 Therapy with T-Lymphocytes Modified with Chimeric Antigen Receptor

Introduction. The production cycle of CAR T-cell product includes several sequential stages, each of which may infl uence the efficiency of transgenic cells: obtaining the patient’s cellular material, isolating the target T-lymphocyte population, activation, transduction of the cells with a viral vector carrying the CAR construct, and expansion of the obtained CAR T-cells with further administration to the patient. Aim: to review the impact of each of the production steps on the cell product performance in both in vitro and in vivo experiments, as well as clinical applications. Main findings . The manufacturing characteristics of various CAR T-cell products were analyzed in this review, followed by a discussion on how different manufacturing characteristics and chimeric antigen receptor structures affect the antitumor efficacy and safety profi le of the cell product. The production of a CAR T-cell product is a multifactorial process that requires optimization of parameters and must take into account the characteristics of the initial raw material (T-lymphocytes).